Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1314 Trilaciclib, an intravenous cyclin-dependent kinase 4/6 inhibitor, enhances antitumor responses by modulating T cells
Compose a Response to This Article
Other responses
No responses have been published for this article.